Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics

Journal of Immunological Methods

Volumn 408, Issue , 2014, Pages 1-12

  Gorovits, Boris ^a   Wakshull, Eric ^b   Pillutla, Renuka ^c   Xu, Yuanxin ^c   Manning, Marta Starcevic ^d   Goyal, Jaya ^e  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

^c BMS ^*  (United States)

^d AMGEN INC   (United States)

^e BIOGEN   (United States)

Author keywords

Anti drug antibody; Immunogenicity response characterization; Multi domain biotherapeutic

Indexed keywords

ALPHA2B INTERFERON; CARRIER PROTEIN; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; EPITOPE; HAPTEN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; MACROGOL; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PEGINTERFERON BETA1A; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY COMPLEX; B LYMPHOCYTE; BIOLOGICAL THERAPY; CELL PROLIFERATION; CELL SURFACE; CHEMICAL STRUCTURE; CLINICAL OBSERVATION; COMPETITIVE INHIBITION; COMPLEMENTARITY DETERMINING REGION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; EPITOPE MAPPING; FALSE NEGATIVE RESULT; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTERNALIZATION; LIGAND BINDING; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE;

ANTI-DRUG ANTIBODY; IMMUNOGENICITY RESPONSE CHARACTERIZATION; MULTI-DOMAIN BIOTHERAPEUTIC;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; EPITOPE MAPPING; EPITOPES; GUIDELINES AS TOPIC; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 84903552494     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.05.010     Document Type: Review

References (58)

1. Armstrong J.K. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylen glycol). PEGylated Protein Drugs: Basic Science and Clinical Applications 2009, 147. Birkhauser Verlag, Switzerland.
2. Bailon P., Won C.-Y. PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 2009, 6:1.
3. Baker D.E. Pegylated interferons. Rev. Gastroenterol. Disord. 2001, 1:87.
4. Buttel I.C., Chamberlain P., Chowers Y., Ehmann F., Greinacher A., Jefferis R., Kramer D., Kropshofer H., Lloyd P., Lubiniecki A., Krause R., Mire-Sluis A., Platts-Mills T., Ragheb J.A., Reipert B.M., Schellekens H., Seitz R., Stas P., Subramanyam M., Thorpe R., Trouvin J.H., Weise M., Windisch J., Schneider C.K. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011, 39:100.
5. Committee for Medicinal Products for Human Use, C Guideline on Immunogenicity Assessment of Biotechnology Derived Therapeutic Proteins 2007, (Doc. Ref. EMEA/CHMP/BMWP/14327/2006).
6. Dalum I., Jensen M.R., Gregorius K., Thomasen C.M., Elsner H.I., Mouritsen S. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol. Immunol. 1997, 34:1113.
7. Deeks E.D. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs 2013, 73:75.
8. Degasperi E., Vigano M., Aghemo A., Lampertico P., Colombo M. PegIFN-alpha2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Rev. Anti-Infect. Ther. 2013, 11:459.
9. Doi T., Ohtsu A., Fuse N., Yoshino T., Tahara M., Shibayama K., Takubo T., Weinreich D.M. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013, 71:227.
10. FDA Draft guideline. Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins 2009.
11. FDA Guidance for industry immunogenicity assessment for therapeutic protein products. Draft Guidance 2013.
12. Finco D., Baltrukonis D., Clements-Egan A., Delaria K., Gunn G.R., Lowe J., Maia M., Wong T. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J. Pharm. Biomed. Anal. 2011, 54:351.
13. Fournier P., Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 2013, 27:35.
14. Ganson N.J., Kelly S.J., Scarlett E., Sundy J.S., Hershfield M.S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 2006, 8:R12.
15. Garay R.P., El-Gewely R., Armstrong J.K., Garratty G., Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 2012, 9:1319.
16. Garrison L., McDonnell N.D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1999, 58(Suppl. 1):I65.
17. Girish S., Gupta M., Wang B., Lu D., Krop I.E., Vogel C.L., Burris Iii H.A., LoRusso P.M., Yi J.-H., Saad O., Tong B., Chu Y.-W., Holden S., Joshi A. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 2012, 69:1229.
18. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1.
19. Harris J.M., Martin N.E., Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 2001, 40:539.
20. Hartung H.-P., Kieseier B.C. Atacicept: targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 2010, 3:205.
21. Hoofring S.A., Lopez R., Hock M.B., Kaliyaperumal A., Patel S.K., Swanson S.J., Chirmule N., Starcevic M. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis 2013, 5:1041.
22. Hu X., Miller L., Richman S., Hitchman S., Glick G., Liu S., Zhu Y., Crossman M., Nestorov I., Gronke R.S., Baker D.P., Rogge M., Subramanyam M., Davar G. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J. Clin. Pharmacol. 2012, 52:798.
23. Inada Y., Furukawa M., Sasaki H., Kodera Y., Hiroto M., Nishimura H., Matsushima A. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 1995, 13:86.
24. Ishizaka K., Okudaira H. Reaginic antibody formation in the mouse. II. Enhancement and suppression of anti-hapten antibody formation by priming with carrier. J. Immunol. 1973, 110:1067.
25. Janssens A. Romiplostim for the treatment of primary immune thrombocytopenia. Expert. Rev. Hematol. 2012, 5:133.
26. Koren E., De Groot A.S., Jawa V., Beck K.D., Boone T., Rivera D., Li L., Mytych D., Koscec M., Weeraratne D., Swanson S., Martin W. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 2007, 124:26.
27. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1.
28. Layton G.T., Stanworth D.R., Amos H.E. Factors influencing the immunogenicity of the haptenic drug chlorhexidine in mice. II. The role of the carrier and adjuvants in the induction of IgE and IgG anti-hapten responses. Immunology 1986, 59:459.
29. Lindsey J.W. Use of reinduced experimental autoimmune encephalomyelitis to evaluate the importance of epitope spread. Int. Immunol. 1998, 10:743.
30. Linke R., Klein A., Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010, 2:129.
31. Liu Y., Reidler H., Pan J., Milunic D., Qin D., Chen D., Vallejo Y.R., Yin R. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J. Pharmacol. Toxicol. Methods 2011, 64:238.
32. Lundquist L.M. Abatacept: a novel treatment for rheumatoid arthritis. Expert. Opin. Pharmacother. 2007, 8:2371.
33. Messinger Y.H., Mendelsohn N.J., Rhead W., Dimmock D., Hershkovitz E., Champion M., Jones S.A., Olson R., White A., Wells C., Bali D., Case L.E., Young S.P., Rosenberg A.S., Kishnani P.S. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet. Med. 2012, 14:135.
34. Miller L.L., Korn E.L., Stevens D.S., Janik J.E., Gause B.L., Kopp W.C., Holmlund J.T., Curti B.D., Sznol M., Smith J.W., Urba W.J., Donegan S.E., Watson T.M., Longo D.L. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood 1999, 93:3250.
35. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1.
36. Mitchison N. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur. J. Immunol. 1971, 1:18.
37. Rosenberg A.S. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. 2003, 112:15.
38. Rosenberg A.S., Verthelyi D., Cherney B.W. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. J. Pharm. Sci. 2012, 101:3560.
39. Sanderson R.J., Hering M.A., James S.F., Sun M.M.C., Doronina S.O., Siadak A.W., Senter P.D., Wahl A.F. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 2005, 11:843.
40. Schellekens H., Hennink W.E., Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 2013, 30:1729.
41. Schouwenburg P.A., Rispens T., Wolbink G.J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 2013, 9:164.
42. Seddon B., Mason D. Deaggregated homologous immunoglobulin-peptide conjugates induce peptide-specific T cell nonresponsiveness in vivo. Eur. J. Immunol. 1998, 28:4313.
43. Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30:631.
44. Shankar G., Shores E., Wagner C., Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 2006, 24:274.
45. Shankar G., Pendley C., Stein K. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 2007, 25:555.
46. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267.
47. Smith H.W., Moxness M., Marsden R. Summary of confirmation cut point discussions. AAPS J. 2011, 13:227.
48. Somerfield J., Hill-Cawthorne G.A., Lin A., Zandi M.S., McCarthy C., Jones J.L., Willcox M., Shaw D., Thompson S.A.J., Compston A.S., Hale G., Waldmann H., Coles A.J. A novel strategy to reduce the immunogenicity of biological therapies. J. Immunol. 2010, 185:763.
49. Stanglmaier M., Faltin M., Ruf P., Bodenhausen A., Schroder P., Lindhofer H. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20×anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int. J. Cancer 2008, 123:1181.
50. Thakur A., Sorenson C., Norkina O., Schalk D., Ratanatharathorn V., Lum L.G. Activated T cells from umbilical cord blood armed with anti-CD3×anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants. Transfusion 2012, 52:63.
51. Tuohy V.K., Yu M., Weinstock-Guttman B., Kinkel R.P. Diversity and plasticity of self recognition during the development of multiple sclerosis. J. Clin. Invest. 1997, 99:1682.
52. Vanderlugt C.L., Neville K.L., Nikcevich K.M., Eagar T.N., Bluestone J.A., Miller S.D. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 2000, 164:670.
53. Waldschmidt T.J., Borel Y., Vitetta E.S. The use of haptenated immunoglobulins to induce B cell tolerance in vitro. The roles of hapten density and the Fc portion of the immunoglobulin carrier. J. Immunol. 1983, 131:2204.
54. Wang X., Ishida T., Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 2007, 119:236.
55. Weidle U.H., Tiefenthaler G., Weiss E.H., Georges G., Brinkmann U. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics 2013, 10:1.
56. Yu M., Johnson J.M., Tuohy V.K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 1996, 183:1777.
57. Zambidis E.T., Scott D.W. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:5019.
58. Zeuzem S., Heathcote J.E., Martin N., Nieforth K., Modi M. Peginterferon alfa-2a (40kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin. Investig. Drugs 2001, 10:2201.